









市場行情
/
股票
/
nasdaq-abvx
/

Abivax SA

ABVX

145.310USD

+6.960+5.03%

收盤 12/24, 13:00（美東）報價延遲15分鐘

0.00總市值

--本益比TTM



Abivax SA

145.310

+6.960+5.03%

概覽公司財務分析

概覽

公司

財務

分析

關於 Abivax SA 公司

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Abivax SA簡介



公司代碼ABVX

公司名稱Abivax SA

上市日期Jun 26, 2015

CEOde Garidel (Marc)

員工數量- -

證券類型Depository Receipt

年結日- -

公司地址7-11 Boulevard Haussmann

城市PARIS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家France

郵編75009

電話33153830963

網址https://www.abivax.com/

公司代碼ABVX

上市日期Jun 26, 2015

CEOde Garidel (Marc)

Abivax SA公司高管



名稱

名稱/職務

職務

持股

持股變動

Senior Vice President - Finance

Kevin Shan

Vice President, Global Head - Biometrics

Ms. Sophie Lacourrege

Vice President, HR Business Partner, Engagement and Culture

Nadege Briancon-eris

Senior Vice President, Global Head - Program Management

Jennifer Fine

Senior Vice President, Global Head - HEOR and RWE

Douglas Jacobstein

Senior Vice President, Global Head - Clinical Development

Mr. Jerome Denis, Ph.D.

Executive Vice President - Process Development & Manufacturing

Mary Mantock

Senior Vice President, Global Head - Regulatory Affairs

Mr. Patrick Malloy

Senior Vice President - Investor Relations

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

名稱

名稱/職務

職務

持股

持股變動

Senior Vice President - Finance

Kevin Shan

Vice President, Global Head - Biometrics

Ms. Sophie Lacourrege

Vice President, HR Business Partner, Engagement and Culture

Nadege Briancon-eris

Senior Vice President, Global Head - Program Management

Jennifer Fine

Senior Vice President, Global Head - HEOR and RWE

Douglas Jacobstein

Senior Vice President, Global Head - Clinical Development

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.06%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

其他

73.34%

持股股東

佔比

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.06%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

其他

73.34%

股東類型

持股股東

佔比

Hedge Fund

33.85%

Investment Advisor

22.65%

Investment Advisor/Hedge Fund

8.69%

Research Firm

2.98%

Venture Capital

2.18%

Private Equity

1.77%

Pension Fund

1.00%

其他

26.88%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

216

53.64M

52.23%

+104.02K

2025Q3

210

53.54M

52.22%

+19.70M

2025Q2

30.74M

57.27%

-1.09M

2025Q1

31.82M

50.24%

-38.10K

2024Q4

29.91M

44.59%

+2.48M

2024Q3

27.43M

45.93%

-700.83K

2024Q2

33.52M

46.25%

-227.21K

2024Q1

28.78M

34.33%

+7.18M

2023Q4

27.04M

1.75%

+20.54M

2023Q3

5.40M

0.00%

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

TCG Crossover Management, LLC

6.06M

8.23%

Jun 30, 2025

Cormorant Asset Management, LP

2.13M

2.9%

Jun 30, 2025

Caligan Partners, LP

1.67M

2.28%

+405.28K

+31.93%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.01M

1.38%

+75.30K

+8.03%

Aug 31, 2025

Adar1 Capital Management LLC

3.07M

4.17%

+861.32K

+38.97%

Jun 30, 2025

Octagon Capital Advisors LP

1.27M

1.72%

+37.00K

+3.01%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Health Care ETF

2.86%

Harbor Health Care ETF

0.7%

Fidelity Nasdaq Composite Index ETF

0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

Innovator IBD Breakout Opportunities ETF

Simplify Health Care ETF

佔比2.86%

Harbor Health Care ETF

佔比0.7%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

佔比0%

Innovator IBD Breakout Opportunities ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Abivax SA的前五大股東是誰？



Abivax SA的前五大股東如下：
TCG Crossover Management, LLC
持有股份：6.06M
佔總股份比例：8.23%。
Cormorant Asset Management, LP
持有股份：2.13M
佔總股份比例：2.90%。
Caligan Partners, LP
持有股份：1.67M
佔總股份比例：2.28%。
Fidelity Management & Research Company LLC
持有股份：1.01M
佔總股份比例：1.38%。
Adar1 Capital Management LLC
持有股份：3.07M
佔總股份比例：4.17%。